Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2003

View Archived Issues

Guangdong Medicine Group signs agreement for Alferon N and Ampligen

Ciprofloxacin GR as effective as Cipro for UTIs

Multiferon gives positive in vitro results against SARS

Good safety and pharmacokinetic profile for oral insulin in type 1 diabetes

High compliance rate, no effects on lung function reported for inhaled insulin in type 2 diabetes

Analgesic efficacy described for LAS-34475 in a model of acute dental pain

Increased insulin sensitivity and glycemic control associated with chromium in type 2 diabetes

GSK scientists identify novel surfactants for inhalable aerosols

Novel GnRH modulators prepared and tested by Pfizer researchers

Biphenyl-based antiandrogenic agents covered by Endorecherche patent

Fujisawa claims novel adenosine deaminase inhibitors and their use

Spanish researchers patent an optically active antifungal agent

Antifungal lipopeptides in early development at Fujisawa

Osiris grants mesenchymal stem cell technology rights to JCR

Valera adopted as new name for Hydro Med Sciences

Continuation of phase I VRX-496 trial recommended

Fibromyalgia advisory meeting for Xyrem proof-of-principle trial

Genzyme seeks Japanese approval of Synvisc

Iseganan designated a fast track drug for VAP

Lumiracoxib safe and effective for moderate to severe postsurgical pain

Low incidence of hypoglycemia reported with insulin glargine in diabetics

Pramlintide induces weight loss and slows gastric emptying in insulin-treated diabetics

Metabolic disease treatments to be developed under Amgen/Biovitrum collaboration

Small molecule selectively targeting HER2 selected for development by Pfizer

Dual inhibitors of HER1/HER2 presented at ACS meeting by Bristol-Myers Squibb

SAR leading to potent, selective and orally active JNK inhibitor AS-601245

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...